Relieves bronchospasm. ANDA 207857, held by Sun Pharmaceutical Industries. Albuterol Sulfate.
As of Nov 18, 2026, ANDA 207857 (Albuterol Sulfate), held by Sun Pharmaceutical Industries, was first approved by FDA on Jul 21, 2017, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Albuterol inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 21, 2017 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Albuterol SulfateEQ 0.083% BASE · solution;inhalation | Albuterol Sulfate | Rx |
| May 28, 2023 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jul 21, 2017 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters